Fostering adherence to injectable disease-modifying therapies in multiple sclerosis

References

• Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 2012;21(11):1679-99
   PubMed Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19(1 Suppl A):S24-40
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Foundation (MSIF). Atlas of MS 2013: mapping multiple sclerosis around the world. Available from: www.msif.org
   Google Scholar
• Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112(1):133-46
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42(5):991-4
   PubMed Web of Science ®Google Scholar
• Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis. Neurology 2013;81(2):184-92
   PubMed Web of Science ®Google Scholar
• Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011;5:73-84
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9
   PubMed Web of Science ®Google Scholar
• Goodin DS, Jones J, Li D, et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2011;6(11):e22444
   PubMedGoogle Scholar
• Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61(4):300-6
   PubMed Web of Science ®Google Scholar
• Tysabri® (natalizumab). Summary of product characteristics. Biogen Idec. 2013
   Google Scholar
• Gilenya® (fingolimod). Summary of product characteristics. Novartis. 2013
   Google Scholar
• Lemtrada® (alemtuzumab). Summary of product characteristics. Genzyme Therapeutics Ltd. 2013
   Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30(2):89-100
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28(1):51-61
   PubMed Web of Science ®Google Scholar
• Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009;6(9):995-1002
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Bennet R, Kozma C, et al. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008;255(Suppl 2):S79
   Google Scholar
• Tremlett H, van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008;17(6):565-76
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J Neurol 2012;259(11):2319-28
   PubMedGoogle Scholar
• Denis L, Namey M, Costello K, et al. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs 2004;36(1):10-22
   PubMedGoogle Scholar
• Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10(9):225
   PubMedGoogle Scholar
• Marinker M, Shaw J. Not to be taken as directed: putting concordance for taking medicines into practice. BMJ 2003;326:348-9
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7
   PubMed Web of Science ®Google Scholar
• Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res 2012;12:98
   PubMed Web of Science ®Google Scholar
• Meyniel C, Spelman T, Jokubaitis VG, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One 2012;7(6):e38661
   Google Scholar
• Lacy M, Hauser M, Pliskin N, et al. The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler 2013;19(13):1765-72
   PubMed Web of Science ®Google Scholar
• Genne M, Lang M, Bergmann A, et al. Betrachtung der adhärenz von patienten mit multipler sklerose unter immunmodulatorischer therapie und deren einflussgrößen in einem ambulanten multipler sklerose zentrum [The adherence of patients with multiple sclerosis to immunomodulator therapy, and influencing factors, in an out-patient multiple sclerosis centre]. 84. Kongress der Deutschen Gesellschaft für Neurologie mit Fortbildungsakademie [84th Congress of the German Society for Neurology Training Academy]; 28 September – 1 October 2011; P674. Poster
   Google Scholar
• Lugaresi A. RebiSmartTM (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv 2013;10(2):273-83
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18(7):932-46
   PubMed Web of Science ®Google Scholar
• O’Rourke K, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11(1):46-50
   PubMedGoogle Scholar
• Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11(3):306-9
   PubMedGoogle Scholar
• Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59(3-4):131-5
   PubMedGoogle Scholar
• Cunningham A, Gottberg K, von Koch L, Hillert J. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand 2010;121(3):154-60
   PubMedGoogle Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67(7):1242-9
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11(1):33-41
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366(11):1000-9
   PubMed Web of Science ®Google Scholar
• Grytten N, Aarseth JH, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurol Scand 2013;127(2):133-40
   PubMed Web of Science ®Google Scholar
• Kappos L, Kuhle J, Gass A, et al. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? J Neurol 2004;251(Suppl 5):v57-64
   Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41(5):685-91
   PubMed Web of Science ®Google Scholar
• Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12(4):549-58
   PubMed Web of Science ®Google Scholar
• Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009;15(1):2-8
   PubMed Web of Science ®Google Scholar
• Ryan KA, Rapport LJ, Sherman TE, et al. Predictors of subjective well-being among individuals with multiple sclerosis. Clin Neuropsychol 2007;21(2):239-62
   PubMed Web of Science ®Google Scholar
• Benedict RHB, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 2011;7(6):332-42
   PubMed Web of Science ®Google Scholar
• DeLuca J, Chelune GJ, Tulsky DS, et al. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J Clin Exp Neuropsychol 2004;26(4):550-62
   PubMed Web of Science ®Google Scholar
• Archibald CJ, Fisk JD. Information processing efficiency in patients with multiple sclerosis. J Clin Exp Neuropsychol 2000;22(5):686-701
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18(1):69-77
   PubMed Web of Science ®Google Scholar
• Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010;33(3):219-27
   PubMed Web of Science ®Google Scholar
• Langdon DW, Amato MP, Boringa J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler 2012;18(6):891-8
   PubMed Web of Science ®Google Scholar
• Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler 2007;13(1):52-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8(11):987-97
   PubMed Web of Science ®Google Scholar
• Penner IK, Stemper B, Calabrese P, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 2012;18(10):1466-71
   PubMed Web of Science ®Google Scholar
• Amato MP, Razzolini L, Goretti B, et al. Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology 2013;80(19):1728-33
   PubMed Web of Science ®Google Scholar
• Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurology 2012;2012:427102
   PubMedGoogle Scholar
• Marrie RA, Horwitz R, Cutter G, et al. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler 2009;15(3):385-92
   PubMedGoogle Scholar
• Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Neurology 2014;82(2):174-81
   PubMed Web of Science ®Google Scholar
• Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59(5):674-8
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54(5):531-3
   PubMedGoogle Scholar
• Benedict RHB, Fishman I, McClellan MM, et al. Validity of beck depression inventory-fast screen in multiple sclerosis. Mult Scler 2003;9(4):393-6
   PubMed Web of Science ®Google Scholar
• Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005;11(3):328-37
   PubMedGoogle Scholar
• Patti F, Amato MP, Trojano M, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler 2011;17(8):991-1001
   PubMed Web of Science ®Google Scholar
• Mattarozzi K, Vignatelli L, Baldin E, et al. Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. Int J Clin Pract 2012;66(5):504-14
   PubMedGoogle Scholar
• Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008;6:100
   PubMed Web of Science ®Google Scholar
• Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 2010;33(8):1061-7
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121-3
   PubMed Web of Science ®Google Scholar
• Elbers RG, Rietberg MB, van Wegen EE, et al. Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties. Qual Life Res 2012;21(6):925-44
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. Expert Opin Pharmacother 2012;13(2):207-16
   PubMed Web of Science ®Google Scholar
• Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984;65:135-8
   PubMed Web of Science ®Google Scholar
• MS Forum. Motivation in multiple sclerosis: slide kit. 2005. Available from: www.msforum.net
   Google Scholar
• Ward-Abel N, Kohler W, Matthews V, et al. Moving towards the pan-European unification of multiple sclerosis nurses: a consensus paper. Mult Scler 2014;20(4):403-5
   PubMed Web of Science ®Google Scholar
• MS Forum. Early management of multiple sclerosis: slide kit. 2003. Available from: www.msforum.net
   Google Scholar
• Heesen C, Kolbeck J, Gold SM, et al. Delivering the diagnosis of MS – results of a survey among patients and neurologists. Acta Neurol Scand 2003;107(5):363-8
   PubMedGoogle Scholar
• Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314(1794):1580-3
   PubMedGoogle Scholar
• Kopke S, Kasper J, Muhlhauser I, et al. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler 2009;15(1):96-104
   PubMed Web of Science ®Google Scholar
• Borreani C, Giordano A, Falautano M, et al. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. Health Expect 2014;17(1):36-48
   PubMed Web of Science ®Google Scholar
• Solari A, Martinelli V, Trojano M, et al. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler 2010;16:1393-405
   PubMed Web of Science ®Google Scholar
• Giordano A, Lugaresi A, Confalonieri P, et al. Implementation of the ‘Sapere Migliora’ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase trial. Mult Scler 2014;20(9):1234-43
   PubMedGoogle Scholar
• Köpke S, Kern S, Ziemssen T, et al. Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2014;85:411-18
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis – results of the BetaPlus observational cohort study. J Neurol Sci 2011;307(1):120-6
   PubMedGoogle Scholar
• Kohlmann T, Wang C, Lipinski J, et al. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status. J Neurosci Nurs 2013;45(3):E3-E14
   Web of Science ®Google Scholar
• Ward-Abel N, Mutch K, Huseyin H. Demonstrating that multiple sclerosis specialist nurses make a difference to patient care. Br J Neurosci Nurs 2010;6(7):319-24
   Google Scholar
• Corry M, McKenna M, Duggan M. The role of the clinical nurse. specialist in MS: a literature review. Br J Nurs 2011;20(2):86-93
   PubMedGoogle Scholar
• Shaw P, McMillan D. Promoting concordance with disease-modifying drugs in MS: the role of the nurse specialist. Br J Neurosci Nurs 2008;4(3):99-105
   Google Scholar
• Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: part II. Rehabil Nurs 2001;26(6):221-6
   PubMedGoogle Scholar
• Marrie RA, Salter AR, Tyry T, et al. Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought. J Med Internet Res 2013;15:e67
   PubMed Web of Science ®Google Scholar
• Haase R, Schultheiss T, Kempcke R, et al. Modern communication technology skills of patients with multiple sclerosis. Mult Scler 2013;19(9):1240-1
   PubMed Web of Science ®Google Scholar
• Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 2013;10(3):285-7
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 2012;12:7
   PubMed Web of Science ®Google Scholar
• Singer B, Wray S, Miller T, et al. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Mult Scler Relat Disord 2012;1(2):87-94
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256(4):568-76
   PubMed Web of Science ®Google Scholar
• Cafazzo JA, Casselman M, Hamming N, et al. Design of an mHealth app for the self-management of adolescent type 1 diabetes: a pilot study. J Med Internet Res 2012;14(3):e70
   PubMed Web of Science ®Google Scholar
• Carter MC, Burley VJ, Nykjaer C, Cade JE. Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial. J Med Internet Res 2013;15(4):e32
   PubMed Web of Science ®Google Scholar
• King D, Greaves F, Exeter C, Darzi A. ‘Gamification’: influencing health behaviours with games. J R Soc Med 2013;106(3):76
   PubMed Web of Science ®Google Scholar
• O’Loughlin EK, Dugas EN, Sabiston CM, O’Loughlin JL. Prevalence and correlates of exergaming in youth. Pediatrics 2012;130(5):806-14
   PubMedGoogle Scholar
• Prosperini L, Fortuna D, Gianni C, et al. Home-based balance training using the Wii balance board: a randomized, crossover pilot study in multiple sclerosis. Neurorehabil Neural Repair 2013;27(6):516-25
   PubMed Web of Science ®Google Scholar
• Shatil E, Metzer A, Horvitz O, Miller O. Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance. NeuroRehabilitation 2010;26(2):143-53
   PubMed Web of Science ®Google Scholar
• Sabate E. Adherence to long-term therapies: evidence for action. WHO; Geneva, Switzerland: 2003
   Google Scholar
• van Dulmen S, Sluijs E, van Dijk L, International Expert Forum on Patient Adherence. Furthering patient adherence: a position paper of the international expert forum on patient adherence based on an internet forum discussion. BMC Health Serv Res 2008;8:47
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008(2):CD000011
   PubMed Web of Science ®Google Scholar
• Heesen C, Bruce J, Feys P, et al. Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. Mult Scler 2014. [Epub ahead of print]
   Google Scholar
• European summary of product characteristics for Betaferon. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf
   Google Scholar